

# TRADEMARK ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																		
NATURE OF CONVEYANCE:	SECURITY INTEREST																		
CONVEYING PARTY DATA																			
<table border="1"> <thead> <tr> <th>Name</th> <th>Formerly</th> <th>Execution Date</th> <th>Entity Type</th> </tr> </thead> <tbody> <tr> <td>Cytochroma Inc.</td> <td></td> <td>09/24/2010</td> <td>CORPORATION: ONTARIO</td> </tr> <tr> <td>Proventiv Therapeutics, LLC</td> <td></td> <td>09/24/2010</td> <td>LIMITED LIABILITY COMPANY: DELAWARE</td> </tr> <tr> <td>Cytochroma Holdings ULC</td> <td></td> <td>09/24/2010</td> <td>Unlited liability corporation: ALBERTA</td> </tr> </tbody> </table>				Name	Formerly	Execution Date	Entity Type	Cytochroma Inc.		09/24/2010	CORPORATION: ONTARIO	Proventiv Therapeutics, LLC		09/24/2010	LIMITED LIABILITY COMPANY: DELAWARE	Cytochroma Holdings ULC		09/24/2010	Unlited liability corporation: ALBERTA
Name	Formerly	Execution Date	Entity Type																
Cytochroma Inc.		09/24/2010	CORPORATION: ONTARIO																
Proventiv Therapeutics, LLC		09/24/2010	LIMITED LIABILITY COMPANY: DELAWARE																
Cytochroma Holdings ULC		09/24/2010	Unlited liability corporation: ALBERTA																
RECEIVING PARTY DATA																			
<table border="1"> <tr> <td>Name:</td> <td>General Electric Capital Corporation</td> </tr> <tr> <td>Street Address:</td> <td>2 Bethesda Metro Center</td> </tr> <tr> <td>Internal Address:</td> <td>Suite 600</td> </tr> <tr> <td>City:</td> <td>Bethesda</td> </tr> <tr> <td>State/Country:</td> <td>MARYLAND</td> </tr> <tr> <td>Postal Code:</td> <td>20814</td> </tr> <tr> <td>Entity Type:</td> <td>CORPORATION: DELAWARE</td> </tr> </table>				Name:	General Electric Capital Corporation	Street Address:	2 Bethesda Metro Center	Internal Address:	Suite 600	City:	Bethesda	State/Country:	MARYLAND	Postal Code:	20814	Entity Type:	CORPORATION: DELAWARE		
Name:	General Electric Capital Corporation																		
Street Address:	2 Bethesda Metro Center																		
Internal Address:	Suite 600																		
City:	Bethesda																		
State/Country:	MARYLAND																		
Postal Code:	20814																		
Entity Type:	CORPORATION: DELAWARE																		
PROPERTY NUMBERS Total: 2																			
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> <th>Word Mark</th> </tr> </thead> <tbody> <tr> <td>Serial Number:</td> <td>78415141</td> <td>CYTOCHROMA</td> </tr> <tr> <td>Serial Number:</td> <td>78768947</td> <td>PROVENTIV THERAPEUTICS</td> </tr> </tbody> </table>				Property Type	Number	Word Mark	Serial Number:	78415141	CYTOCHROMA	Serial Number:	78768947	PROVENTIV THERAPEUTICS							
Property Type	Number	Word Mark																	
Serial Number:	78415141	CYTOCHROMA																	
Serial Number:	78768947	PROVENTIV THERAPEUTICS																	
CORRESPONDENCE DATA																			
<p>Fax Number: (404)541-4710</p> <p><i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i></p> <p>Phone: 704-338-5220</p> <p>Email: laallen@kilpatrickstockton.com</p> <p>Correspondent Name: My Ngo, Esq.</p> <p>Address Line 1: Kilpatrick Stockton LLP</p> <p>Address Line 2: 1100 Peachtree Street, Suite 2800</p> <p>Address Line 4: Atlanta, GEORGIA 30309</p>																			

OP \$65.00 78415141

900172486

TRADEMARK  
 REEL: 004285 FRAME: 0050

ATTORNEY DOCKET NUMBER:	393624
NAME OF SUBMITTER:	Latosh E. Allen
Signature:	/Latosha E. Allen/
Date:	09/27/2010
<p><b>Total Attachments: 19</b></p> <p>source=Intellectual Property Security Agreement#page1.tif  source=Intellectual Property Security Agreement#page2.tif  source=Intellectual Property Security Agreement#page3.tif  source=Intellectual Property Security Agreement#page4.tif  source=Intellectual Property Security Agreement#page5.tif  source=Intellectual Property Security Agreement#page6.tif  source=Intellectual Property Security Agreement#page7.tif  source=Intellectual Property Security Agreement#page8.tif  source=Intellectual Property Security Agreement#page9.tif  source=Intellectual Property Security Agreement#page10.tif  source=Intellectual Property Security Agreement#page11.tif  source=Intellectual Property Security Agreement#page12.tif  source=Intellectual Property Security Agreement#page13.tif  source=Intellectual Property Security Agreement#page14.tif  source=Intellectual Property Security Agreement#page15.tif  source=Intellectual Property Security Agreement#page16.tif  source=Intellectual Property Security Agreement#page17.tif  source=Intellectual Property Security Agreement#page18.tif  source=Intellectual Property Security Agreement#page19.tif</p>	

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this "**Agreement**"), dated as of September 24, 2010, is made by **CYTOCHROMA INC.** ("**Borrower**"), **PROVENTIV THERAPEUTICS, LLC** ("**Proventiv**"), and **CYTOCHROMA HOLDINGS ULC** ("**Holdings**"; together with Proventiv and Borrower, each a "**Grantor**" and together, "**Grantors**"), in favor of **GENERAL ELECTRIC CAPITAL CORPORATION**, a Delaware corporation, in its capacity as agent (in such capacity, together with any successors, endorsees and assigns, the "**Agent**") for itself and the lenders from time to time party to the Loan Agreement hereinafter defined (collectively, the "**Lenders**").

### W I T N E S S E T H:

**WHEREAS**, Grantors, Agent and Lenders are parties to the Loan Agreement, dated as of the date hereof (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "**Loan Agreement**"), pursuant to which Lenders have agreed to provide to Borrower certain loans and other extensions of credit in accordance with the terms and conditions thereof; and

**WHEREAS**, pursuant to that certain (i) Guaranty and Security Agreement, by and between Grantors and Agent, dated as of the date hereof (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "**U.S. Guaranty**") and (ii) Canadian Guarantee and Security Agreement, by and between Grantors and Agent, dated as of the date hereof (as the same may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "**Canadian Guaranty**"; together with the U.S. Guaranty, the "**Guaranty**"), Grantors are required to execute and deliver this Agreement.

**NOW, THEREFORE**, in consideration of the premises and mutual covenants herein contained and to induce Agent and Lenders to enter into the Loan Agreement and to induce the Lenders to make their respective extensions of credit to Borrower, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantors hereby agree with the Agent as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Loan Agreement.

Section 2. Grant of Security Interest in Intellectual Property Collateral. Each Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations hereby mortgages, pledges and hypothecates to Agent, for the benefit of itself and Lenders, and grants to Agent, for the benefit of itself and Lenders, a Lien on and security interest in, all of its right, title and interest in, to and under the Intellectual Property of Grantor, including the following (collectively, the "**Intellectual Property Collateral**"):

(a) all of its trade secrets and rights under any written agreement granting any right to use trade secrets other than those which constitute CTA018 Technologies;

(b) all of its copyrights and rights under any written agreement granting any right to use copyrights, including, without limitation, those referred to on Schedule 1 hereto, together with all renewals, reversions and extensions of the foregoing other than those which constitute CTA018 Technologies;

(c) all of its trademarks, servicemarks, trade names, trade dress or other indicia of trade origin and rights under any written agreement granting any right to use such trademarks, servicemarks, trade names, trade dress or other indicia of trade origin, including, without limitation, those referred to on Schedule 2 hereto, together with all renewals, reversions and extensions of the foregoing but excluding any of the foregoing which constitute CTA018 Technologies and any "intent-to-use" trademark applications for which a statement of use has not been filed (but only until such statement is filed);

(d) all goodwill of the business connected with the use of, and symbolized by, each such trademark covered by clause (c) above;

(e) all of its US and Canadian patents and rights under any written agreement granting any right to use US and Canadian patents other than those set forth on Schedule 7 hereto, including, without limitation, those owned by Grantor referred to on Schedule 3 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(f) all of its US and Canadian patent applications and rights under any written agreement granting any right to use US patent and Canadian patent applications other than those set forth on Schedule 7 hereto, including, without limitation, those owned by Grantor referred to on Schedule 4 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(g) all of its PCT patent applications and rights under any written agreement granting any right to use PCT patent applications other than those set forth on Schedule 7 hereto, including, without limitation, those owned by Grantor referred to on Schedule 5 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(h) all of its other foreign patents and patent applications, and rights under any written agreement granting any right to use foreign patents and patent applications other than those set forth on Schedule 7 hereto but including, without limitation, those owned by Grantor referred to on Schedule 6 hereto, together with all reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals and extensions of the foregoing;

(i) all applications, registrations, claims, products, awards, judgments, amendments, improvements and insurance claims related thereto now or hereafter owned or licensed by Grantor, or any claims for damages by way of any past, present, or future infringement of any of the foregoing, together with all accessions and additions thereto, proceeds and products thereof (including, without limitation, any proceeds resulting under insurance policies); provided, further, that the Intellectual Property Collateral shall include, without limitation, all cash, royalty fees, other proceeds, accounts and general intangibles that consist of rights of payment to or on behalf of Grantor or proceeds from the sale, licensing or other

disposition of all or any part of, or rights in, the Intellectual Property Collateral by or on behalf of Grantor; and

(j) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

For the avoidance of doubt, the foregoing Intellectual Property Collateral shall exclude CTA018 Technologies until such time as the Intellectual Property no longer comprises CTA018 Technologies, at which time it shall automatically constitute Intellectual Property Collateral.

Section 3. Loan Agreement. The security interest granted pursuant to this Agreement is granted in conjunction with, and is in no way limiting, the security interest granted to Agent, for the benefit of itself and Lenders, pursuant to the applicable Guaranty, and each Grantor hereby acknowledges and agrees that the rights and remedies of Agent and Lenders with respect to the security interest in the Intellectual Property Collateral made and granted hereby are more fully set forth in the Loan Agreement and other Debt Documents, the terms and provisions of each of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantors Remains Liable. Grantors hereby agree that, anything herein to the contrary notwithstanding, Grantors shall retain full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with their Intellectual Property subject to a security interest hereunder.

Section 5. Counterparts. This Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.

Section 6. Governing Law. This Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York without reference to its provisions of conflicts of laws.

*[Signature Pages Follow]*

In witness whereof, each Grantor has caused this Intellectual Property Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

**GRANTORS:**

**CYTOCHROMA INC.**

By: Charles W. Bishop  
Name: CHARLES W. BISHOP  
Title: President & CEO

**PROVENTIV THERAPEUTICS, LLC**

By: Charles W. Bishop  
Name: CHARLES W. BISHOP  
Title: President & CEO

**CYTOCHROMA HOLDINGS ULC**

By: Charles W. Bishop  
Name: CHARLES W. BISHOP  
Title: President & CEO

CYTOCHROMA, INC.  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE

ACCEPTED AND AGREED  
as of the date first above written:

**GENERAL ELECTRIC CAPITAL CORPORATION,**  
as Agent

By: 

Name: R. Hanes Whiteley

Title: Duly Authorized Signatory

CYTOCHROMA, INC.  
INTELLECTUAL PROPERTY SECURITY AGREEMENT  
SIGNATURE PAGE


TRADEMARK  
REEL: 004285 FRAME: 0056

Acknowledgment of Grantor

STATE OF Illinois )  
COUNTY OF Lake ) ss

On this 23<sup>rd</sup> day of September 2010 before me personally appeared Charles Bishop, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of **CYTOCHROMA, INC.**, who being by me duly sworn did depose and say that he is an authorized officer of said corporation, that the said instrument was signed on behalf of said corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said corporation.

Judith L. Sandahl  
Notary Public



ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

TRADEMARK  
REEL: 004285 FRAME: 0057




Acknowledgment of Grantor

STATE OF Illinois )  
COUNTY OF Lake ) ss

On this 22<sup>nd</sup> day of September 2010 before me personally appeared Charles Bishop, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of **CYTOCHROMA HOLDINGS ULC**, who being by me duly sworn did depose and say that he is an authorized officer of said unlimited liability corporation, that the said instrument was signed on behalf of said unlimited liability corporation as authorized by its Board of Directors and that he acknowledged said instrument to be the free act and deed of said unlimited liability corporation.

Judith A. Sandahl  
Notary Public




ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

Acknowledgment of Grantor

STATE OF Illinois )  
COUNTY OF Lake ) ss

On this 23<sup>rd</sup> day of September 2010 before me personally appeared Charles Bishop, proved to me on the basis of satisfactory evidence to be the person who executed the foregoing instrument on behalf of **PROVENTIV THERAPEUTICS, LLC**, who being by me duly sworn did depose and say that he is an authorized officer of said limited liability company, that the said instrument was signed on behalf of said limited liability company as authorized by its members and that he acknowledged said instrument to be the free act and deed of said limited liability company.

Judith L. Sandahl  
Notary Public



ACKNOWLEDGEMENT OF GRANTOR  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

**OWNERSHIP KEY FOR ALL INTELLECTUAL PROPERTY SCHEDULES:**

**\* indicates Intellectual Property owned, co-owned, or licensed by Cytochroma Inc.**

**\*\* indicates Intellectual Property owned, co-owned, or licensed by Proventiv Therapeutics  
LLC**

**\*,\*\* indicates Intellectual Property co-owned by Cytochroma Inc. and Proventiv  
Therapeutics LLC**

**Schedule 1**  
**COPYRIGHTS**

None

**Schedule 2  
TRADEMARKS**

Mark: CYTOCHROMA & Design

<b>Country</b>	<b>Application Number</b>	<b>Application Date</b>	<b>Comment</b>
U.S.*	78/415,141	April 28, 2004	
Canada*	1,215,000	April 28, 2004	Allowed

Mark: PROVENTIV THERAPEUTICS & Design

<b>Country</b>	<b>Application Number</b>	<b>Application Date</b>	<b>Comment</b>
U.S.**	78/768,947	December 7, 2005	

**Schedule 3**  
**PATENTS**

**US**

U.S. Patent No. 7,288,407 \*

U.S. Patent No. 7,427,670 \*

U.S. Patent No. 7,537,919 \*

U.S. Patent No. 7,115,558 \*

U.S. Patent No. 7,579,329 \*

U.S. Patent No. 7,335,756 \*

U.S. Patent No. 6,063,606 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

U.S. Patent No. 6,306,624 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

U.S. Patent No. 6,861,238 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

U.S. Patent No. 7,473,422 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

U.S. Patent No. 7,335,484 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

U.S. Patent No. 6,096,876 \* (owned by Shriners Hospital for Children; Licensed to Cytochroma Inc.)

**CANADIAN**

Canadian Patent No. 2,366,586 \* (owned by The Johns Hopkins University; Licensed to Cytochroma Inc.)

Canadian Patent No. 2,334,347 \* (owned by The Johns Hopkins University; Licensed to Cytochroma Inc.)

**Schedule 4**  
**PATENT APPLICATIONS**

US

U.S. Patent Application No. 12/109,983 \*,\*\*

U.S. Patent Application No. 12/278,053 \*\*

U.S. Patent Application No. 12/597,224 \*,\*\*

U.S. Patent Application No. 12/403,271 \*

U.S. Patent Application No. 11/549,001 \*\*

U.S. Patent Application No. 12/597,230 \*

U.S. Patent Application No. 12/305,572 \*,\*\*

U.S. Patent Application No. 12/597,234 \*\*

U.S. Patent Application No. 12/546,450 \*

U.S. Patent Application No. 12/447,385 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

U.S. Patent Application No. 12/447,193 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

U.S. Patent Application No. 12/447,338 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

U.S. Patent Application No. 12/314,893 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

U.S. Provisional Patent Application No. 61/318,741 \*,\*\*

CANADIAN

Canadian Patent Application No. 2,683,997 \*,\*\*

Canadian Patent Application No. 2,640,094 \*\*

Canadian Patent Application No. 2,684,778 \*,\*\*

Canadian Patent Application No. 2,624,897 \*\*

Canadian Patent Application No. 2,683,628 \*

Canadian Patent Application No. 2,655,499 \*,\*\*

Canadian Patent Application No. 2,683,514 \*\*

Canadian Patent Application No. 2,484,244 \*

Canadian Patent Application No. 2,494,572 \*

Canadian Patent Application No. 2,396,511 \*

Canadian Patent Application No. 2,448,933 \*

Canadian Patent Application No. 2,688,083 \*

Canadian Patent Application No. 2,488,334 \* (co-owned with The Johns Hopkins University)

Canadian Patent Application No. 2,458,415 \* (co-owned with The Johns Hopkins University)

Canadian Patent Application No. 2,463,505 \* (co-owned with The Johns Hopkins University)

Canadian Patent Application No. 2,510,228 \* (co-owned with The Johns Hopkins University)

Canadian Patent Application No. 2,605,815 \* (co-owned with The Johns Hopkins University)

Canadian Patent Application No. 2,257,352 \* (owned by Queen's University at Kingston;  
Licensed to Cytochroma Inc.)

Canadian Patent Application No. 2,667,524 \* (owned by Wisconsin Alumni Research  
Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Canadian Patent Application No. 2,667,613 \* (owned by Wisconsin Alumni Research  
Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Canadian Patent Application No. 2,667,563 \* (owned by Wisconsin Alumni Research  
Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)



**Schedule 5**  
**PCT PATENT APPLICATIONS**

PCT Patent Application No. PCT/CA2009/000291 \*

PCT Patent Application No. PCT/CA2009/001687 \*

PCT Patent Application No. PCT/US2010/33419 \*

PCT Patent Application No. PCT/US2009/39355 \*,\*\*

PCT Patent Application No. PCT/CA2010/000111 \*

**Schedule 6**  
**FOREIGN PATENTS**

European Patent No. 1,419,143 \* (co-owned with The Johns Hopkins University; validated in Italy, Switzerland, United Kingdom, France, Germany)

European Patent No. 1,436,257 \* (co-owned with The Johns Hopkins University; validated in The Netherlands, Denmark, Sweden, Monaco, Greece, Finland, Belgium, Luxembourg, Spain, Switzerland, Austria, France, Portugal, Italy, Germany, Cyprus, United Kingdom, Ireland)

European Patent No. 1,180,035 \* (owned by The Johns Hopkins University; Licensed to Cytochroma Inc.; validated in The Netherlands, Denmark, Sweden, Monaco, Greece, Finland, Belgium, Luxembourg, Spain, Switzerland, Austria, France, Portugal, Italy, Germany, Cyprus, United Kingdom, Ireland)

European Patent No. 1,095,017 \* (owned by The Johns Hopkins University; Licensed to Cytochroma Inc.; validated in Italy, Switzerland, United Kingdom, France, Germany)

European Patent No. 0,910,644 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.; validated in Ireland, Switzerland, United Kingdom, France, Germany, Belgium)

Japanese Patent No. 4,283,342 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

South African Patent No. 97/5541 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

Indian Patent No. 186,424 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

Indian Divisional Patent No. 230,846 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

Australian Patent No. 778,362 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

Mexican Patent No. 252,551 \* (owned by Queen's University at Kingston; Licensed to Cytochroma Inc.)

Mexican Patent No. 221,757 \* (owned by The Johns Hopkins University; Licensed to Cytochroma Inc.)

European Patent Application No. 08746908.6 \*,\*\*

European Patent Application No. 07763210.7 \*\*

European Patent Application No. 08746915.1 \*,\*\*

European Patent Application No. 06836270.6 \*\*

European Patent Application No. 08837933.4 \*

European Patent Application No. 07840277.3 \*,\*\*

European Patent Application No. 08746920.1 \*\*

European Patent Application No. 08762721.2 \*

European Patent Application No. 03727105.3 \* (co-owned with The Johns Hopkins University)

European Patent Application No. 06721850.3 \* (co-owned with The Johns Hopkins University)

European Patent Application No. 07844528.4 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

European Patent Application No. 07871216.3 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

European Patent Application No. 07844535.0 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

European Divisional Patent Application No. 06020197.7 \* (owned by The Johns Hopkins University; Licensed to Cytochroma Inc.)

Japanese Patent Application No. 2010-506520 \*,\*\*

Japanese Patent Application No. 2008-553520 \*\*

Japanese Patent Application No. 2010-506521 \*,\*\*

Japanese Patent Application No. 2008-535659 \*\*

Japanese Patent Application No. 2010-504912 \*

Japanese Patent Application No. 2009-516725 \*,\*\*

Japanese Patent Application No. 2010-506524 \*\*

Japanese Patent Application No. 2010-508281 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Japanese Patent Application No. 2010-508282 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Japanese Patent Application No. 2010-508283 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Chinese Patent Application No. 200880013357.6 \*,\*\*

Chinese Patent Application No. 200880013367.X \*

Chinese Patent Application No. 2007080048005 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Chinese Patent Application No. 2007080048139 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Chinese Patent Application No. 2007080048219 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

South Korean Patent Application No. 10-2009-7024328 \*,\*\*

South Korean Patent Application No. 10-2009-7024309 \*

Indian Patent Application No. 2514/CHENP/2009 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Indian Patent Application No. 2878/CHENP/2009 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Indian Patent Application No. 2882/CHENP/2009 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Australian Patent Application No. 2007309029 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Australian Patent Application No. 2007325459 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Australian Patent Application No. 2007309026 \*(owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Brazilian Patent Application No. 018090020851 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Brazilian Patent Application No. 018090020840 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

Brazilian Patent Application No. 018090020846 \* (owned by Wisconsin Alumni Research Foundation and aOvatechnologies, Inc; Licensed to Cytochroma Inc.)

**Schedule 7**  
**ENCUMBERED PATENTS**

U.S. Patent No. 7,101,865 \* (co-owned with The Johns Hopkins University)

U.S. Patent No. 7,166,585 \* (co-owned with The Johns Hopkins University)

Japanese Patent No. 4,490,262 \* (co-owned with The Johns Hopkins University)

U.S. Divisional Patent Application No. 11/442,148 \* (co-owned by The Johns Hopkins University)

U.S. Provisional Patent Application No. 61/294,741 \* (co-owned with The Johns Hopkins University)

SCHEDULE 7  
INTELLECTUAL PROPERTY SECURITY AGREEMENT

US2008 1503141.6

**RECORDED: 09/28/2010**

**TRADEMARK**  
**REEL: 004285 FRAME: 0070**